Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

PURPOSE: Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both. The goal of this randomized phase II study was to evaluate two differe...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Clarke, Jennifer L., Iwamoto, Fabio M., Sul, Joohee, Panageas, Katherine, Lassman, Andrew B., DeAngelis, Lisa M., Hormigo, Adília, Nolan, Craig P., Gavrilovic, Igor, Karimi, Sasan, Abrey, Lauren E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2009
Pynciau:
Original Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727290/
https://ncbi.nlm.nih.gov/pubmed/19506159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.7944
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg